Arda Ural. PhD is a Partner in EY's Transaction Advisory Services (TAS) and leads Operational Integration and Separation Transactions Practice for Life Sciences sector in the US.
Prior to joining EY, Arda was a Managing Director at Accenture Strategy M&A for six years. Earlier, Arda worked as a VP of Strategic Marketing and a BU Lead at Becton Dickinson. He also served as the SVP Marketing & Sales for a start-up biotechnology company Eyetech (later acquired by OSI/Astellas).
Arda started his career with Pfizer in Istanbul and subsequently relocated to New York where he held leadership roles in product commercialization and new product development such as launching Viagra worldwide and leading Celebrex US team.
He holds BSc & MSc degrees in Mechanical Engineering from the Bosporus University and an MBA and PhD from the Marmara University in Istanbul, Turkey in Finance and Strategy. He also completed Executive Development Program at Harvard Business School.
Arda is a member of the BioNJ Business Development Executive Advisory Committee and a member of the board of trustees for Brooklyn Conservatory of Music, a not-for-profit institution serving underprivileged communities over 120 years including programs such as music therapy for children with learning disabilities. He is also on the business advisory board of New Jersey Institute of Technology (NJIT).
Arda is an author of several whitepapers and a frequent speaker about biopharmaceutical trends and strategy in industry conferences including BIO.